SCHEDULE: Venrock Healthcare Group Boosts Ocular Therapeutix Stake

Venrock Healthcare Capital Partners and affiliates report a 7.3% beneficial ownership stake in Ocular Therapeutix Inc., totaling 12.9 million shares.

Summary

• Venrock Healthcare Capital Partners III, L.P., along with its affiliates VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and individuals Nimish Shah and Bong Koh, collectively reported beneficial ownership of 12,913,420 shares of Ocular Therapeutix Inc. common stock.
• This aggregate ownership represents 7.3% of Ocular Therapeutix Inc.'s outstanding common stock as of September 30, 2025.
• The reported percentage is based on 174,949,558 shares of common stock outstanding as of September 30, 2025, plus 2,145,639 shares issuable upon the exercise of Pre-Funded Warrants.
• The beneficial ownership includes 10,767,781 shares of common stock and 2,145,639 shares underlying immediately exercisable Pre-Funded Warrants.
• All reporting persons share both voting and dispositive power over the 12,913,420 shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued institutional investment by a specialized healthcare capital firm, which is generally viewed positively as a vote of confidence in the company's prospects. The nature of a 13G is purely informational regarding ownership, so it doesn't contain operational or financial news that would drastically shift sentiment, but the presence of such an investor is a positive signal.

Positives

• A significant 7.3% stake by a reputable healthcare capital firm like Venrock indicates institutional confidence in Ocular Therapeutix Inc.'s long-term potential and strategic direction.
• The inclusion of Pre-Funded Warrants suggests a strategic investment that could provide additional capital to the company upon exercise, although the warrants are already held by the reporting persons.

Negatives

• The filing itself, being a routine ownership disclosure, does not inherently contain negative financial or operational information about Ocular Therapeutix Inc.

Risks

• The filing does not explicitly detail risks for Ocular Therapeutix Inc.; it is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Ocular Therapeutix Inc. or the reporting persons regarding the company's future performance.

Industry Context

The investment by Venrock Healthcare Capital Partners, a specialized healthcare venture capital firm, in Ocular Therapeutix Inc. (a biopharmaceutical company) aligns with broader industry trends of institutional investors seeking opportunities in innovative healthcare and biotech companies. Such investments often signal confidence in a company's drug pipeline, market potential, or technological advancements within the ophthalmology sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Venrock Healthcare Capital Partners may instill confidence among existing shareholders and attract new investors, potentially influencing stock valuation.
• Company Management: A large institutional investor often implies increased scrutiny and potential influence on strategic decisions, though the filing states the investment is not for control purposes.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by Venrock Healthcare Capital Partners and its affiliates in Ocular Therapeutix Inc. While a substantial institutional investment can be seen as a positive signal of confidence in the company's long-term prospects, this filing alone does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It confirms continued institutional interest, suggesting a 'hold' position for investors who believe in the company's fundamentals, pending further operational updates or financial results.

Keywords

Ocular Therapeutix, Venrock Healthcare Capital Partners, VHCP, Beneficial Ownership, Schedule 13G, Common Stock, Pre-Funded Warrants, Institutional Investor, Biotechnology, Pharmaceuticals